Breast Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_2_3340 - Non-metastatic inflammatory breast cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Non-metastatic inflammatory breast cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis
S. Shamp1, and T. Biswas2; 1University Hospitals Cleveland Medical Center, Cleveland, OH, 2University Hospitals Seidman Cancer Center, Cleveland, OH

Purpose/Objective(s): To examine the survival outcomes in non-metastatic inflammatory breast cancer based on tumor histology, patient characteristics, and treatment received.

Materials/Methods: 1776 patients with pathologically confirmed non-metastatic inflammatory breast cancer (AJCC 7th ed. cT4dNanyM0) who were diagnosed in 2010-2014 were analyzed retrospectively utilizing the SEER 18 database. Median age 56 (range 20-99) years. Median follow-up 21 months (range 1-60). 99.7% female, 0.3% male. Patient distribution by receptor status was HR+/Her2- 35% (n=626), HR-/Her2+ 16% (n=285), HR+/Her2+ 18% (n=314) and Triple negative 24% (n=425). Mastectomy was performed in 74.3% of patients, 21.3% no surgery, 3.5% lumpectomy, 1.0% unknown. A majority of patients received External Beam radiation (n=996, 56%). A majority of patients received chemotherapy (n=1559, 88%). 26.1% died (n=464), with 22.0% attributed to breast cancer (n=391). We analyzed overall survival (OS) from the date of diagnosis using Kaplan-Meier survival analysis. Cox regression multivariate analysis was performed for comparisons of hazard ratio (HR) among subgroups.

Results: Among 4 histology subtypes, OS was best in HR+/Her2+ (2-yr OS 89%; 4-yr OS 78%), and worst in triple negative (2-yr OS 54%; 4-yr OS 40%), with HR+/Her2- (2-yr OS 82%; 4-yr OS 64%) and HR-/Her2+ (2-yr OS 81%; 4-yr OS 69%) in-between (p<0.001). External beam radiation improved OS significantly in patients receiving (MS not reached; 2-yr OS 85%; 4-yr OS 70%) compared to no radiation (MS 40 months; 2-yr OS 61%; 4-yr OS 47%) (p<0.0001). Cox multivariable analysis demonstrated improved HR with HR+/Her2+ receptor status (HR 0.62, range 0.42-0.91), Grade I (HR 0.26, range 0.10-0.70) and Grade II (HR 0.67, range 0.50-0.89), Asian race (HR 0.43, range 0.23-0.82). Worse OS was associated with older age at diagnosis (HR 1.02 per year, range 1.01-1.03), Triple negative receptor status (HR 2.92, range 2.22-3.83), AJCC 7th N2 (HR 1.92, range 1.40-2.62), N3 (HR 2.53, range 1.88-3.40), Black race (HR 1.63, range 1.18-2.24), and not receiving radiation (HR 1.74, range 1.33-2.27), chemotherapy (HR 1.73, range 1.20-2.48), or surgery (HR 1.51, range 1.11-2.05). Laterality and sex were not significant predictors of OS.

Conclusion: This is the largest population based breast cancer report showing various demographic patterns and OS in non-metastatic inflammatory breast cancer based on different breast cancer subtypes and treatment received.

Author Disclosure: S. Shamp: None. T. Biswas: None.

Send Email for Stephen Shamp


Assets

TU_2_3340 - Non-metastatic inflammatory breast cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Non-metastatic inflammatory breast cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis